The earnings call highlighted significant progress in clinical trials and regulatory advancements, bolstered by a strong financial position and strategic collaborations. However, these positives are tempered by ongoing arbitration with Servier and a decrease in cash reserves.

Company Guidance -

Q3 2025

During Cellectis' Second Quarter 2025 Earnings Call, the company provided comprehensive guidance on various fronts. It announced the completion of Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, with plans to initiate a pivotal Phase II trial in the second half of 2025. The call also highlighted ongoing recruitment for the NatHaLi-01 study of UCART20x22 in relapsed or refractory non-Hodgkin lymphoma, with Phase I data submission for the ASH Annual Conference in Q4 2025. Additionally, Cellectis discussed its arbitration with Servier, expecting a decision by December 15, 2025. Financially, the company reported cash, cash equivalents, and fixed-term deposits totaling $230 million as of June 30, 2025, down from $264 million at the end of 2024, primarily due to operational expenses. This funding is deemed sufficient to support operations into H2 2027. Furthermore, Cellectis reiterated its commitment to advancing its cell and gene therapy programs with AstraZeneca and announced an Investor R&D Day scheduled for October 16, 2025, to present detailed Phase I data and development strategies.

Initiation of Pivotal Phase II Trial

Cellectis is preparing for the initiation of the pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025.

Financial Position

Cellectis' cash, cash equivalents, and fixed-term deposits as of June 30, 2025, amount to $230 million, sufficient to fund operations into H2 2027.

Progress in Clinical Trials

Recruitment to the dose escalation component of the Phase I BALLI-01 study evaluating UCART22 is complete. Cellectis is expanding trial sites in the US and Europe for Phase II.

Productive Regulatory Feedback

Cellectis received clear guidance from both the FDA and EMA on endpoints, study design, and statistical plans for lasme-cel, paving a clear path for the Phase II program.

Strategic Collaboration with AstraZeneca

Ongoing R&D activities under the partnership with AstraZeneca include three cell and gene therapy programs, with progress noted in allogeneic CAR-T for hematological malignancies and solid tumors.

Cellectis SA (CMVLF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CMVLF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.23 / -	-0.245	―	―	―
Aug 04, 2025	2025 (Q2)	-0.22 / -0.24	-0.297	18.75% (+0.06)	―
May 12, 2025	2025 (Q1)	-0.16 / -0.19	0.086	-317.57% (-0.27)	―	―
Mar 13, 2025	2024 (Q4)	-0.20 / -0.18	-0.696	73.96% (+0.51)	―
Nov 04, 2024	2024 (Q3)	-0.25 / -0.25	-0.337	27.24% (+0.09)	―
Aug 06, 2024	2024 (Q2)	-0.30 / -0.30	-0.2	-48.84% (-0.10)	―	―
May 28, 2024	2024 (Q1)	-0.36 / 0.09	-0.612	114.04% (+0.70)	―
Mar 11, 2024	2023 (Q4)	-0.31 / -0.09	-0.648	86.56% (+0.56)	―	―
Nov 06, 2023	2023 (Q3)	-0.45 / -0.34	-0.74	54.47% (+0.40)	―
Aug 03, 2023	2023 (Q2)	-0.46 / -0.20	-0.48	58.35% (+0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CMVLF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$3.12	$3.12	0.00%
May 12, 2025	$1.25	$1.25	0.00%
Mar 13, 2025	$1.25	$1.25	0.00%
Nov 04, 2024	$1.99	$1.99	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cellectis SA (CMVLF) report earnings?

Cellectis SA (CMVLF) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).

What is Cellectis SA (CMVLF) earnings time?

Cellectis SA (CMVLF) earnings time is at Nov 10, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CMVLF EPS forecast?

CMVLF EPS forecast for the fiscal quarter 2025 (Q3) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing